Evidence mapPaperPMID 40944272Full record

ReviewNutrients2025

The Neuroprotective Role of Curcumin: From Molecular Pathways to Clinical Translation-A Narrative Review.

Andrea Lehoczki, Mónika Fekete, Tamás Jarecsny, Virág Zábó, Ágnes Szappanos, Tamás Csípő, Ágnes Lipécz, Dávid Major, Vince Fazekas-Pongor, Péter Varga and 1 more

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea LehoczkiInstitute of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-4285-7518
Mónika FeketeInstitute of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0001-8632-2120
Tamás JarecsnyDepartment of Neurology and Stroke, Saint John's Central Hospital of North Buda, 1125 Budapest, Hungary.ORCID 0000-0002-8419-5292
Virág ZábóFodor Center for Prevention and Healthy Aging, Semmelweis University, 1085 Budapest, Hungary.
Ágnes SzappanosHeart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.
Tamás CsípőInstitute of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.
Ágnes LipéczInstitute of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.ORCID 0009-0003-7608-3041
Dávid MajorInstitute of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-6108-9745
Vince Fazekas-PongorInstitute of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-6405-4003
Péter VargaInstitute of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.
János Tamás VargaDepartment of Pulmonology, Semmelweis University, 1083 Budapest, Hungary.ORCID 0000-0002-8552-1336

Funding

GEROSCIENCE TRAINING PROGRAM IN OKLAHOMAT32AG052363 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$373k
Time-restricted feeding (TRF) for prevention of age-related vascular cognitive impairment and dementiaR03AG070479 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Stefano Tarantini · 2022 to 2022
$290k
Midlife Obesity, Neurovascular Senescence and Cognitive DeclineK01AG073614 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$120k
National Cardiovascular Laboratory Program RRF-2.3.1-21-2022-00003National Research, Development and Innovation Fund TKP2021-NKTA-47NIA NIH HHS K01 AG073614NIA NIH HHS R03 AG070479NIA NIH HHS T32 AG052363
6 · The paper itself

Abstract

Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and post-stroke cognitive impairment (PSCI), represent an escalating global health and economic challenge. In the quest for disease-modifying interventions, natural polyphenols-most notably curcumin, the principal bioactive compound of Curcuma longa-have attracted considerable interest due to their pleiotropic neuroprotective effects. This narrative review critically synthesizes findings from a selection of peer-reviewed articles published between 2000 and 2025, chosen for their relevance to curcumin's molecular mechanisms and translational potential. Curcumin's complex chemical structure confers antioxidant, anti-inflammatory, and epigenetic modulatory properties; however, its clinical application is limited by poor oral bioavailability. Mechanistically, curcumin attenuates oxidative stress and suppresses key inflammatory mediators, including nuclear factor kappa B (NF-κB), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS). Additionally, it modulates apoptosis, inhibits amyloid-beta aggregation, and enhances cellular quality control processes such as autophagy and mitophagy, while upregulating neurotrophic factors such as brain-derived neurotrophic factor (BDNF). Preclinical studies employing rodent models of AD, PD, and ischemic stroke have demonstrated curcumin's dose-dependent neuroprotective efficacy, with improved outcomes observed using nanoparticle-based delivery systems. Early-phase clinical trials further support curcumin's favorable safety profile and potential cognitive benefits, although challenges remain regarding pharmacokinetics, formulation standardization, and therapeutic reproducibility. Future directions include the development of advanced drug delivery platforms, combinatory therapeutic regimens, and personalized medicine approaches integrating curcumin within multifaceted neurotherapeutic strategies. Collectively, this narrative review highlights curcumin as a promising multi-targeted candidate for combating neurodegenerative diseases, while emphasizing the need for further translational and clinical validation.

Indexed as

CurcuminNeurodegenerative DiseasesNeuroprotective AgentsAnimalsHumansOxidative StressTranslational Research, BiomedicalCurcuminNeuroprotective AgentsAlzheimer’s diseaseclinical translationcurcuminnarrative reviewneurodegenerationneuroinflammationoxidative stressParkinson’s diseasepolyphenols

Identifiers

PMID40944272
PMCPMC12430471

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.